All In Biotech

Drug Trial Radar · NCT04510207

A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above

Multicenter, Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above

Last checked: Nov 20, 2026Latest source record: Jun 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 44,101 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

44,101

Actual

Start

Jul 16, 2020

Primary completion

Jun 16, 2021

Study completion Dec 31, 2021

Sponsor

Sponsor type
Industry
Collaborators
G42 Healthcare Research Technology Projects LLC; Abu Dhabi Health Services Company; Wuhan Institute of Biological Products Co., Ltd; Beijing Institute of Biological Products Co Ltd.
First posted
Aug 12, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double blind, parallel placebo controlled, phase 3 clinical trial to evaluate the protective efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy population 18 years old and above.

Conditions

  • COVID-19

Interventions

  • Inactivated SARS-CoV-2 Vaccine (Vero cell)Biological

    The inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by WIBP

  • Inactivated SARS-CoV-2 Vaccine (Vero cell)Biological

    The inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by BIBP

  • PlaceboBiological

    The placebo of inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by WIBP

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of COVID-19 cases after two-doses of vaccinationTime frame: From14 days after the second dose to 6 month after the second dose
  2. The incidence of COVID-19 cases after the booster dose of immunizationTime frame: From 14 days after the booster dose

Locations

6 sites in 4 countries. Site status is shown where the registry gives one.

  • Bahrain International Exhibition & Convention Centre Affiliated to Salymynia Medical Complex S

    Sanābis, Bahrain

  • Katameya Medical Center

    Cairo, Egypt

  • Vacsera health Care facilities , MoH

    Cairo, Egypt

  • Prince Hamza Hospital

    Amman, Jordan

  • Sheikh Khalifa Medical City, SEHA

    Abu Dhabi, United Arab Emirates

  • Al Qarain Primary Health Care Centre-MOHAP

    Sharjah city, United Arab Emirates

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.